Carbon dot-amino acid composite reagent as well as preparation method and application thereof

By heating the near-infrared emitted carbon nanodots with dextrorogenic acids, a carbon dot-amino acid complex reagent is formed, which solves the problem of poor therapeutic effect of carbon nanodots in tumor photothermal therapy, and achieves enhanced near-infrared luminescence and light Thermal conversion characteristics improve the fluorescence imaging and treatment effects of tumors and simplify the preparation process.

CN119055784APending Publication Date: 2024-12-03UNIV OF MACAU
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411196915.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing carbon nanodots have poor therapeutic effects on tumor photothermal therapy without increasing particle size, and there are challenges in achieving efficient near-infrared luminescence and photothermal conversion efficiency, which affects their biomedical applications.

Method used

By heating and recombining the near-infrared-emitting carbon nanodots and dextro-amino acids in the solution system, a carbon dot-amino acid complex reagent is formed, and the electron-absorbing group on the surface of the carbon nanodots is used to bind to the dextro-amino acid through non-covalent bonds to enhance Near infrared luminescence characteristics and photothermal conversion characteristics, and prolong blood circulation time in the body to improve tumor enrichment ability.

Benefits of technology

The carbon dot-amino acid composite reagent has been realized to enhance near-infrared luminescence and photothermal conversion characteristics, extend the blood circulation time in the body, improve the fluorescence imaging and photothermal treatment effects of tumors, and the preparation method is simple, low-priced, and easy to large. Massive preparation in scale.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055784A_ABST
    Figure CN119055784A_ABST
Patent Text Reader

Abstract

The invention discloses a carbon dot-amino acid composite reagent as well as a preparation method and application thereof, and relates to the technical field of carbon nanomaterials. The carbon dot-amino acid composite reagent provided by the invention comprises carbon nanodots and amino acid which are compounded with each other, wherein the carbon nanodots are near infrared emission carbon nanodots; the amino acid is dextral amino acid. The carbon dot-amino acid composite reagent is formed by combining electron withdrawing groups on the surfaces of the carbon nanodots and dextral amino acid through non-covalent bonds, and the carbon dot-amino acid composite reagent shows enhanced near-infrared luminescence characteristics and good photothermal conversion characteristics. The carbon dot-amino acid composite preparation has prolonged blood circulation time in vivo by utilizing the characteristic of slow metabolism speed of the dextro-amino acid in vivo, and the enrichment capacity of the carbon dot-amino acid composite preparation at a tumor part is improved, so that fluorescence imaging and photo-thermal treatment of tumors are realized. The preparation method of the carbon dot-amino acid composite reagent is simple, low in price and easy for large-scale batch preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of carbon nanomaterials, and in particular to a carbon dot-amino acid composite reagent and a preparation method and application thereof. Background Art

[0002] Carbon dots (CDs), as an emerging ultra-small carbon nanomaterial, have unique advantages, including low toxicity, good biocompatibility, tunable bandgap emission, and diverse photophysical properties. Nowadays, CD-based biomedical applications have attracted extensive attention, especially in fluorescence (FL) imaging and tumor therapy. The utilization of near-infrared (NIR) luminescent CDs is advantageous because of their enhanced tissue imaging capabilities and higher penetration depth. Achieving efficient NIR luminescence in CDs is a major challenge.

[0003] Among tumor treatment methods, tumor photothermal therapy (PTT) has unique advantages and minimal side effects. However, due to the competing photophysical processes of FL (radiative transition) and PTT (non-radiative transition), achieving efficient NIR emission and high photothermal conversion efficiency is a major challenge. Therefore, balancing the FL and photothermal processes in CDs is of great significance for broadening their biomedical functional applications. Simultaneously achieving efficient NIR luminescence and effective tumor photothermal therapy remains a challenge for CDs. In addition, improving the enrichment efficiency of CDs in tumors usually requires increasing the particle size, which can improve tumor targeting but raises concerns about in vivo enrichment.

[0004] It can be seen that the existing methods for preparing carbon nanodots generally have the following problems: the prepared carbon nanodots have poor PTT treatment effects without increasing the particle size.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide a carbon dot-amino acid composite reagent and a preparation method and application thereof to solve the above technical problems.

[0007] The present invention is achieved in that:

[0008] In a first aspect, an embodiment of the present invention provides a carbon dot-amino acid composite reagent, which includes carbon nanodots and amino acids composited with each other; wherein the carbon nanodots are near-infrared emitting carbon nanodots; and the amino acids are dextrorotatory amino acids.

[0009] In a second aspect, an embodiment of the present invention provides a method for preparing the aforementioned carbon dot-amino acid composite reagent, the preparation method comprising: heating and composite the carbon nanodots and dextrorotatory amino acids in a solution system.

[0010] In a third aspect, an embodiment of the present invention provides a use of the aforementioned carbon dot-amino acid composite reagent or the carbon dot-amino acid composite reagent prepared by the aforementioned preparation method in preparing a biological imaging reagent.

[0011] In a fourth aspect, an embodiment of the present invention provides a use of the carbon dot-amino acid composite reagent as described above or the carbon dot-amino acid composite reagent prepared by the preparation method as described above in photothermal therapy of tumors.

[0012] The present invention has the following beneficial effects:

[0013] The carbon dot-amino acid composite reagent provided in the embodiment of the present invention utilizes the electron-withdrawing groups on the surface of carbon nanodots and dextrorotatory amino acids to form a carbon nanodot amino acid reagent by non-covalent bonds, showing enhanced near-infrared luminescence characteristics and good photothermal conversion characteristics. Taking advantage of the slow metabolism of dextrorotatory amino acids in the body, the carbon dot-amino acid composite preparation has a prolonged blood circulation time in the body, thereby increasing the enrichment capacity at the tumor site, thereby achieving fluorescence imaging and photothermal therapy of the tumor. The preparation method of the carbon dot-amino acid composite reagent is simple, low-cost, and easy to prepare in large quantities. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0015] Figure 1 TEM image of the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1;

[0016] Figure 2 This is the absorption spectrum of the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1 in aqueous solution;

[0017] Figure 3 The emission spectrum of the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1 (under 550 nm laser excitation);

[0018] Figure 4 This is the emission spectrum of the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1 (under 630 nm laser excitation);

[0019] Figure 5 Photothermal performance analysis of the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1;

[0020] Figure 6 This is a diagram of the experimental phenomenon of intracellular imaging of the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1;

[0021] Figure 7 This is a tissue fluorescence image of the in vivo metabolism time of the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1;

[0022] Figure 8 This is a diagram of the experimental phenomenon of animal imaging of the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1;

[0023] Fig. 9 This is a diagram of the experimental phenomenon of photothermal therapy of tumors using the carbon dot-amino acid composite reagent (D-Arg@CDs) prepared in Example 1. DETAILED DESCRIPTION

[0024] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0025] In a first aspect, an embodiment of the present invention provides a carbon dot-amino acid composite reagent, which includes carbon nanodots and amino acids composited with each other; wherein the carbon nanodots are near-infrared emitting carbon nanodots; and the amino acids are dextrorotatory amino acids.

[0026] It should be noted that the carbon nanodots of the present invention are near-infrared emitting carbon nanodots, which have the following characteristics:

[0027] Near-infrared emitting carbon nanodots can generate a new luminescence band gap in the near-infrared band and achieve efficient near-infrared luminescence; they are non-toxic and have excellent biocompatibility, which makes them safer when used in vivo and reduces potential toxic reactions, and have great application prospects in the biomedical field; they achieve efficient absorption and luminescence in the near-infrared band, achieve deeper penetration in biological tissues, effectively increase tissue penetration depth and reduce autofluorescence interference, which is of great significance for their clinical application.

[0028] In addition, the surface of the near-infrared emitting carbon nanodots has electron-withdrawing groups, which can be complexed with dextrorotatory amino acids. The electron-withdrawing groups on the surface of the carbon nanodots can serve as hydrogen bond acceptor groups. The dextrorotatory amino acids are then combined with the carbon nanodots through hydrogen bonds without the need for complicated purification procedures to form a carbon nanodot-dextrorotatory amino acid complex reagent.

[0029] The carbon dot-amino acid composite reagent prepared by the present invention can simultaneously have near-infrared luminescence and high photothermal functional conversion efficiency CDs.

[0030] As mentioned above, the carbon dot-amino acid composite reagent provided by the present invention can also be called carbon nanodot-dextrorotatory amino acid composite near-infrared reagent.

[0031] In an optional embodiment of the present invention, the dextrorotatory amino acid is selected from at least one of dextrorotatory arginine, dextrorotatory lysine and dextrorotatory histidine.

[0032] It should be noted that amino acids are organic compounds composed of two groups, amino and carboxyl, which are connected by a carbon atom. This carbon atom is called the alpha carbon atom, and it has four different chemical groups around it: an amino group (NH2), a carboxyl group (COOH), a hydrogen atom, and a side chain (R). If the four groups around the alpha carbon atom of an amino acid are arranged in a clockwise direction, then this amino acid is a right-handed amino acid. If the four groups around the alpha carbon atom of an amino acid are arranged in a clockwise direction, then this amino acid is a right-handed amino acid.

[0033] Dextrorotatory amino acids are optically and biologically active, among which dextrorotatory arginine, dextrorotatory lysine and dextrorotatory histidine can form composite materials with near-infrared carbon nanodots. Dextrorotatory amino acids play different roles in the body's metabolic process and are usually used as raw materials for drugs or in nutritional supplements. In addition, dextrorotatory amino acids have different applications in the fields of medicine, health care and agriculture. However, only left-handed amino acids usually exist in organisms, while dextrorotatory amino acids rarely appear. This is because enzymes and other enzymes in organisms can only recognize and catalyze left-handed amino acids, but not dextrorotatory amino acids. If too many dextrorotatory amino acids are ingested, they will not be absorbed by the body and may have a negative impact on human health.

[0034] It should be noted that arginine is an essential amino acid that is essential for maintaining the normal function of the body. It plays a role in protein synthesis, wound healing, immune regulation, cardiovascular health, etc. Lysine is an alkaline essential amino acid that the human body cannot synthesize on its own and must be taken in through the diet. It plays an important role in protein synthesis, maintaining muscle mass, promoting growth and development, and strengthening the immune system. Histidine is a semi-essential amino acid that the human body can synthesize part of on its own, but in some cases it still needs to be taken in from the diet. It plays an important role in protein synthesis, immune response, and maintaining the health of the nervous system.

[0035] In a preferred embodiment of the present invention, the dextrorotatory amino acid is dextrorotatory arginine.

[0036] It should be noted that D-arginine (D-Arg) is a non-essential amino acid for the human body. It can enhance the near-infrared luminescence of CDs and prolong its metabolic time in the body, thereby increasing the tumor enrichment rate and significantly improving the effect of photothermal therapy.

[0037] In an optional embodiment of the present invention, the mass ratio of carbon nanodots to dextrorotatory amino acids is 1:(1-100).

[0038] Specifically, the mass ratio of carbon nanodots to dextrorotatory amino acids is selected from any one of 1:1, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, or other ratio values ​​between 1:(1-100).

[0039] It should be noted that controlling the mass ratio of carbon nanodots and right-handed amino acids within the above range can further improve the near-infrared fluorescence quantum yield of the composite reagent while taking into account its photothermal performance.

[0040] In a preferred embodiment of the present invention, the mass ratio of carbon nanodots to dextrorotatory amino acids is 1:(1-10).

[0041] It should be noted that the photothermal performance of the carbon dot-amino acid composite reagent prepared when the mass ratio of carbon nanodots to dextrorotatory amino acids is within the above range is slightly reduced, but it can still maintain a relatively high temperature enhancement value of about 70°C after the same laser irradiation.

[0042] In an optional embodiment of the present invention, the surface of the carbon nanodots has electron-withdrawing groups.

[0043] It should be noted that the source of carbon nanodots is not particularly limited in the present invention. As long as the carbon nanodots used have electron-withdrawing groups on the surface, they can form hydrogen bonds with right-handed amino acids. For example, carbon nanodots include but are not limited to carbon dots prepared from citric acid and urea.

[0044] Furthermore, in an embodiment of the present invention, the carbon nanodots are prepared by solvothermal reaction of citric acid and urea, and the solvent includes dimethyl sulfoxide.

[0045] Specifically, the preparation of carbon nanodots includes the following steps:

[0046] Dissolve citric acid and urea in dimethyl sulfoxide (DMSO), put them into a reactor, heat them at high temperature, and perform a solvent thermal reaction. After the reaction is completed, centrifuge the product system, and then freeze-dry the lower precipitate to obtain carbon nanodots. The mass ratio of citric acid to urea can be 1:3, the temperature of the solvent thermal reaction can be 150℃-200℃, such as 160℃, etc., and the time is 3h-5h, such as 4h, etc.

[0047] In an optional embodiment of the present invention, the carbon dot-amino acid composite reagent is a nanoparticle with a particle size of 2nm-10nm. Nanoparticles of this particle size can have better uptake performance, easily enter cells, and have better fluorescence imaging effect.

[0048] In an optional embodiment of the present invention, the main absorption band of the carbon dot-amino acid complex reagent in water is 520nm-700nm; further, the absorption band is 550nm-650nm.

[0049] And / or, the carbon dot-amino acid complex reagent has an emission peak at 500nm-800nm ​​under excitation by a light source in the ultraviolet-visible light region; preferably, under excitation at 550nm, the emission peak is at 650nm.

[0050] In a second aspect, an embodiment of the present invention provides a method for preparing the aforementioned carbon dot-amino acid composite reagent, the preparation method comprising: heating and composite the carbon nanodots and dextrorotatory amino acids in a solution system.

[0051] It should be noted that the preparation method of the carbon dot-amino acid composite reagent is simple, low-cost, and easy to prepare in large quantities.

[0052] In an optional embodiment of the present invention, the heating compounding is carried out in an aqueous solution so that the carbon nanodots and the dextrorotatory amino acids can react sufficiently and evenly.

[0053] In an optional embodiment of the present invention, the concentration of the dextrorotatory amino acid in the aqueous solution is 1 mg·mL -1 -50mg·mL -1 .

[0054] In an optional embodiment of the present invention, the temperature of the heating compound is 30° C.-80° C., and the time of the heating compound is 5 min-30 min.

[0055] It should be noted that within the above temperature and heating time, the right-handed amino acid and the near-infrared luminescent carbon nanodots can fully react and combine together to form composite nanoparticles with uniform particle size, and have better near-infrared fluorescence quantum yield and good luminescence performance.

[0056] Specifically, the temperature of the heating compound can be 30°C, 45°C, 50°C, 60°C, etc., or any value between the above adjacent temperature values. The time of the heating compound can be 5min, 10min, 15min, 20min, 25min, 30min, etc., or any value between the above adjacent time values.

[0057] In an optional embodiment of the present invention, the preparation method further comprises performing solid-liquid separation after heating and compounding, and drying the solid.

[0058] Furthermore, the solid-liquid separation method is selected from any one of dialysis separation and column chromatography, and the drying method is freeze-drying.

[0059] It should be noted that dialysis separation uses a semipermeable membrane. During the dialysis process, the property that small molecules can pass through the semipermeable membrane in the solution, while large molecules cannot, is used to achieve separation and further purify the product.

[0060] Specifically, in an embodiment of the present invention, the solid-liquid mixture obtained after heating and compounding is put into a dialysis bag (molecular weight cut-off is 1000Da) and dialyzed with ultrapure water for half a day. In other embodiments of the present invention, column chromatography can also be used for solid-liquid separation as needed.

[0061] In other embodiments of the present invention, the dialysis treatment time can be reasonably adjusted according to the actual amount of material being treated.

[0062] In a third aspect, an embodiment of the present invention provides a use of the aforementioned carbon dot-amino acid composite reagent or the carbon dot-amino acid composite reagent prepared by the aforementioned preparation method in preparing a biological imaging reagent.

[0063] It should be noted that the near-infrared reagent of the carbon dot-dextrorotatory amino acid complex is applied in biological imaging, specifically in fluorescent imaging of cells and animal imaging.

[0064] In a fourth aspect, an embodiment of the present invention provides a use of the carbon dot-amino acid composite reagent as described above or the carbon dot-amino acid composite reagent prepared by the preparation method as described above in photothermal therapy of tumors.

[0065] It should be noted that the carbon dot right-handed amino acid reagent helps to prolong the metabolic time in the blood circulation, thereby improving the accumulation efficiency at the tumor site in the mouse model, thereby achieving efficient photothermal therapy performance.

[0066] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0067] Example 1

[0068] This embodiment provides a carbon dot-amino acid composite reagent, the preparation process of which includes the following steps:

[0069] 2 g of citric acid and 6 g of urea were dissolved in 30 mL of dimethyl sulfoxide (DMSO), and the liquid was placed in a 50 mL polytetrafluoroethylene high-pressure reactor for heating reaction at a temperature of 160°C for 4 hours in an oven. 60 mL of ethanol was added to the solution after the reaction, and the reaction was centrifuged at a speed of 10,000 rpm to remove the upper solution, leaving a precipitate, which was centrifuged 3 times. The lower precipitate was freeze-dried to obtain a black solid powder, namely carbon nanodots (CDs).

[0070] The prepared CDs and water were mixed to obtain a CDs aqueous solution with a concentration of 1 mg / mL, and 1 mL of the CDs aqueous solution was added to 1 mL of D-Arg (dextrorotatory arginine) aqueous solution, and the concentration of the D-Arg aqueous solution was 10 mg / mL. The mixed solution was heated at 40°C for 15 minutes, and the solution after the reaction was placed in a dialysis bag (molecular weight cutoff of 1000 Da), dialyzed with ultrapure water for half a day, and freeze-dried to obtain a carbon dot-amino acid composite reagent (D-Arg@CDs).

[0071] Example 2

[0072] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the concentration of the D-Arg aqueous solution is 5 mg / mL.

[0073] Example 3

[0074] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the concentration of the D-Arg aqueous solution is 20 mg / mL.

[0075] Example 4

[0076] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the concentration of the D-Arg aqueous solution is 30 mg / mL.

[0077] Example 5

[0078] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the concentration of the D-Arg aqueous solution is 40 mg / mL.

[0079] Example 6

[0080] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the concentration of the D-Arg aqueous solution is 50 mg / mL.

[0081] Example 7

[0082] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the mixed solution is heated at 40° C. for 5 minutes.

[0083] Example 8

[0084] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the mixed solution is heated at 45° C. for 10 minutes.

[0085] Example 9

[0086] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the mixed solution is heated at 50° C. for 5 minutes.

[0087] Example 10

[0088] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in the preparation process: the mixed solution is heated at 60° C. for 10 minutes.

[0089] Example 12

[0090] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in that during the preparation process, dextrorotatory arginine is replaced by l-arginine.

[0091] Embodiment 13

[0092] This embodiment provides a carbon dot-amino acid composite reagent, which is different from Embodiment 1 only in that during the preparation process, D-arginine is replaced by D-lysine.

[0093] Test Example 1

[0094] In this test example, the CDs and D-Arg@CDs obtained in Example 1 were analyzed by transmission electron microscopy. The instrument model was FEITecnai-G2-F30 (Georgia Tech), and the relevant parameters were 200 kV. The specific transmission electron microscope TEM image is as follows Figure 1 As shown, (a) is CDs and (b) is D-Arg@CDs.

[0095] Depend on Figure 1 It can be seen that the particle size of D-Arg@CDs is between 2nm and 10nm, and the average size is about 5nm.

[0096] Test Example 2

[0097] In this test example, the optical properties of D-Arg@CDs obtained in Example 1 were observed by absorption and fluorescence spectra PL, and the relevant instrument models were UV-2600 spectrometer (Shimadzu) and Edinburgh FS5 spectrophotometer. Figure 2-Figure 4 ,in, Figure 2 The absorption spectrum of D-Arg@CDs in aqueous solution is shown in Figure 2. Figure 3 The emission spectrum of D-Arg@CDs (under 550nm laser excitation) is shown. Figure 4 It represents the emission spectrum of D-Arg@CDs (under 630nm laser excitation); Figure 2-Figure 4 The ratio in is the ratio of carbon nanodots to right-handed amino acids.

[0098] Depend on Figure 2 It can be seen that in aqueous solution, the UV-visible absorption band of D-Arg@CDs at 665 nm is first enhanced and slightly blue-shifted, and then gradually decreases as the D-arginine content increases to 10 times that of CDs.

[0099] Depend on Figure 3 and Figure 4 It can be seen that when the D-arginine content increased to 10 times that of CDs, the FL emission bands of the CDs and D-arginine complex peaked at 550 nm and 630 nm, respectively, and the enhancement of the emission bands gradually slowed down when the D-arginine content increased further.

[0100] Test Example 3

[0101] In this test example, the photothermal performance of D-Arg@CDs obtained in Example 1 was analyzed. The relevant test instrument was FLIR, and the instrument model was E52. The specific results are shown in Figure 5 .

[0102] from Figure 5 It can be seen that after CDs and D-arginine are compounded at a mass ratio of no more than 10 times, the photothermal performance of D-Arg@CDs decreases slightly, but it can still maintain a high temperature enhancement value of about 70 °C after the same laser irradiation.

[0103] Test Example 4

[0104] In this test example, the cell staining performance of D-Arg@CDs obtained in Example 1 was tested. The specific test process is as follows: a certain density of Hepa1-6 cells were inoculated into a 6-well plate with a cover glass bottom and cultured for 24 hours, then the culture medium was replaced with D-Arg@CDs solution and cultured for another 1.5 hours; finally, the stained slide was observed by Zeiss LSM880 confocal laser scanning microscope. Related test results are shown in Figure 6 .

[0105] from Figure 6 It can be seen that under 543 nm laser excitation, clear red FL images of Hepa1-6 cells incubated with D-Arg@CDs for 1.5 h were observed. In contrast, the red FL signal in cells incubated with CDs was much weaker. These results demonstrate the high-efficiency cellular uptake of D-Arg@CDs for bioimaging and biomedical applications.

[0106] Test Example 5

[0107] In this test example, the in vivo metabolism time of D-Arg@CDs obtained in Example 1 was tested. The relevant test results are shown in 7.

[0108] from Figure 7 It can be seen that major organs (heart, liver, spleen, lung, and kidney - in order from top to bottom) were removed at different time points (1h, 3h, 12h, 24h, and 48h) after intravenous injection of CDs, D-Arg@CDs, and L-Arg@CDs for ex vivo fluorescence imaging.

[0109] Before injection, major organs showed no red fluorescence under 589nm laser excitation. One hour after intravenous injection of D-Arg@CDs, the liver and kidney showed red fluorescence signals under the same 589nm laser excitation. For CDs and L-Arg@CDs, these signals gradually weakened and eventually disappeared 24 hours after injection. However, even after 48 hours, the kidneys still showed fluorescence for D-Arg@CDs, indicating that D-Arg@CDs were metabolized for a longer time in mice.

[0110] Test Example 6

[0111] In this test example, the animal imaging performance of the D-Arg@CDs obtained in Example 1 was tested. The relevant test results are shown in Figure 8.

[0112] from Figure 8 It can be seen that after intravenous injection of CDs, D-Arg@CDs and L-Arg@CDs, the mice showed strong red fluorescence throughout the body within the first hour, and the fluorescence gradually weakened after 6 hours. After CDs were modified with D-Arg and L-Arg, both D-Arg@CDs and L-Arg@CDs accumulated in tumor tissues, and D-Arg@CDs stayed in tumor tissues longer, indicating that D-arginine can prolong the metabolism of CDs in the body and increase their accumulation in tumor tissues.

[0113] Test Example 7

[0114] In this test example, the photothermal therapy performance of D-Arg@CDs obtained in Example 1 was tested. The specific test process is as follows: After intravenous injection of CDs, D-Arg@CDs and L-Arg@CDs, a 655nm laser was used at 1w / cm 2 The tumor site was irradiated at a power of , and the relevant test results are shown in 9.

[0115] from Fig. 9 It can be seen that in the control group, tumor tissue continued to grow over time, and neither D-Arg@CDs nor laser irradiation alone showed effective inhibition of tumor progression. However, in the CDs PTT group, only marginal inhibition of tumor growth was observed, which was mainly attributed to the relatively low photothermal temperature achieved. In contrast, the group of mice treated with D-Arg@CDs showed significant and obvious tumor growth inhibition, resulting in complete ablation, and no recurrence was observed even after 60 days.

[0116] In summary, the carbon dot-amino acid composite reagent provided by the present invention exhibits enhanced near-infrared luminescence properties and good photothermal conversion properties; it has a prolonged blood circulation time in the body, thereby increasing the enrichment capacity at the tumor site, thereby realizing fluorescence imaging and photothermal therapy of the tumor; the preparation method of the carbon dot-amino acid composite reagent is simple, low-cost, and easy to prepare on a large scale.

[0117] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A carbon dot-amino acid composite reagent, characterized in that: The carbon dot-amino acid composite reagent includes carbon nanodots and amino acids composited with each other; The carbon nanodots are near-infrared emitting carbon nanodots; and the amino acids are dextrorotatory amino acids.

2. The carbon dot-amino acid composite reagent according to claim 1, characterized in that: The dextrorotatory amino acid is selected from at least one of dextrorotatory arginine, dextrorotatory lysine and dextrorotatory histidine; Preferably, the dextrorotatory amino acid is dextrorotatory arginine.

3. The carbon dot-amino acid composite reagent according to claim 1, characterized in that: The mass ratio of the carbon nanodots to the dextrorotatory amino acid is 1:(1-100); Preferred is 1:(1-10).

4. The carbon dot-amino acid composite reagent according to claim 1, characterized in that: The surface of the carbon nanodots has electron-withdrawing groups; Preferably, the carbon nanodots are prepared by solvothermal reaction of citric acid and urea, and the solvent includes dimethyl sulfoxide; Preferably, the carbon dot-amino acid composite reagent is a nanoparticle with a particle size of 2nm-10nm.

5. The carbon dot-amino acid composite reagent according to claim 1, characterized in that: The main absorption band of the carbon dot-amino acid composite reagent in water is 520nm-700nm; preferably, the absorption band is 550nm-650nm; And / or, the carbon dot-amino acid complex reagent has an emission peak at 500nm-800nm ​​under excitation of a light source in the ultraviolet-visible light region; preferably, under excitation at 550nm, the emission peak is at 650nm.

6. A method for preparing the carbon dot-amino acid composite reagent according to any one of claims 1 to 5, characterized in that: The preparation method comprises: The carbon nanodots and the right-handed amino acid are heated and compounded in a solution system.

7. The preparation method according to claim 6, characterized in that: The heating compounding is carried out in an aqueous solution; Preferably, the concentration of the right-handed amino acid in the aqueous solution is 1 mg mL -1 -50mg·mL -1 ; Preferably, the temperature of the heating compound is 30°C-80°C, and the time of the heating compound is 5min-30min.

8. The preparation method according to claim 6, characterized in that: The preparation method further comprises performing solid-liquid separation after heating and compounding, and drying the solid; Preferably, the solid-liquid separation method is selected from any one of dialysis separation and column chromatography, and the drying method is freeze-drying.

9. Use of the carbon dot-amino acid composite reagent as described in any one of claims 1 to 5 or the carbon dot-amino acid composite reagent prepared by the preparation method as described in any one of claims 6 to 8 in preparing a biological imaging reagent.

10. Use of the carbon dot-amino acid composite reagent as described in any one of claims 1 to 5 or the carbon dot-amino acid composite reagent prepared by the preparation method as described in any one of claims 6 to 8 in photothermal therapy of tumors.

Citation Information

Cited By

  • Amino acid-porous carbon dot composite material as well as preparation method and application thereof

    CN121136698A